

## Documents

Zainal Fithri, H.H.<sup>a</sup>, Ibrahim, Z.<sup>a b</sup>, Ali, E.Z.<sup>c</sup>

**Impact of GSK199 and GSK106 binding on protein arginine deiminase IV stability and flexibility: A computational approach**

(2023) *Computational Biology and Chemistry*, 107, art. no. 107962, .

DOI: 10.1016/j.compbiolchem.2023.107962

<sup>a</sup> Department of Pharmaceutical Chemistry, Kulliyah of Pharmacy, International Islamic University Malaysia, Indera Mahkota, Pahang, Kuantan, 25200, Malaysia

<sup>b</sup> Drug Discovery and Synthetic Chemistry Research Group, Kulliyah of Pharmacy, International Islamic University Malaysia, Indera Mahkota, Pahang, Kuantan, 25200, Malaysia

<sup>c</sup> Inborn Error of Metabolism and Genetic Unit, Nutrition, Metabolism and Cardiovascular Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Section U13 Setia Alam, Selangor, Shah Alam, 40170, Malaysia

**Abstract**

Protein arginine deiminase IV (PAD4) is a potential target for diseases including rheumatoid arthritis and cancers. Currently, GSK199 is a potent, selective yet reversible PAD4 inhibitor. Its derivative, GSK106, on the other hand, was reported as an inactive compound when tested against PAD4 assay. Although they had similar skeleton, their impact towards PAD4 structural and flexibility is unknown. In order to fill the research gap, the impact of GSK199 and GSK106 binding towards PAD4 stability and flexibility is investigated via a combination of computational methods. Molecular docking indicates that GSK199 and GSK106 are capable to bind at PAD4 pocket by using its back door with  $-10.6$  kcal/mol and  $-9.6$  kcal/mol, respectively. The simulations of both complexes were stable throughout 100 ns. The structure of PAD4 exhibited a tighter packing in the presence of GSK106 compared to GSK199. The RMSF analysis demonstrates significant changes between the PAD4-GSK199 and PAD4-GSK106 simulations in the regions containing residues 136, 160, 220, 438, and 606. The Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) analysis shows a marked difference in binding free energies, with  $-11.339$  kcal/mol for the PAD4-GSK199 complex and  $1.063$  kcal/mol for the PAD4-GSK106 complex. The hydrogen bond analysis revealed that the GSK199 and GSK106 binding to PAD4 are assisted by six hydrogen bonds and three hydrogen bonds, respectively. The visualisation of the MD simulations revealed that GSK199 remained in the PAD4 pocket, whereas GSK106 shifted away from the catalytic site. Meanwhile, molecular dockings of benzoyl arginine amide (BAEE) substrate have shown that BAEE is able to bind to PAD4 catalytic site when GSK106 was present but not when GSK199 occupied the site. Overall, combination of computational approaches successfully described the behaviour of binding pocket of PAD4 structure in the presence of the active and inactive compounds. © 2023 Elsevier Ltd

**Author Keywords**

GSK106; GSK199; MD simulation and MMPBSA; PAD4

**Index Keywords**

Amides, Arginine, Binding energy, Complexation, Computational methods, Diseases, Molecular modeling, Proteins; Arginine deiminases, Computational approach, Gsk106, Gsk199, Inactive compounds, MD simulation, MD simulation and molecular mechanic poisson-boltzmann surface area, PAD4, Poisson-Boltzmann, Surface area; Hydrogen bonds

**References**

- Abraham, M.J.  
**Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers**  
(2015) *SoftwareX*, 1-2, pp. 19-25.
- Agnihotry, S., Pathak, R.K., Singh, D.B., Tiwari, A., Hussain, I.  
**Protein structure prediction**  
(2022) *Bioinforma.: Methods Appl.*, pp. 177-188.
- Baka, Z.  
**Citrullination under physiological and pathological conditions**  
(2012) *Jt. Bone Spine*, 79, pp. 431-436.  
(Preprint at)
- Bordogna, A., Pandini, A., Bonati, L.  
**Predicting the accuracy of protein-ligand docking on homology models**

- (2011) *J. Comput. Chem.*, 32, pp. 81-98.
- Bruggeman, Y.  
**Targeting citrullination in autoimmunity: insights learned from preclinical mouse models**  
(2021) *Expert Opin. Ther. Targets*, 25, pp. 269-281.
  - Buono, R.J.  
**Genetic variation in PADI6-PADI4 on 1p36.13 is associated with common forms of human generalized epilepsy**  
(2021) *Genes (Basel)*, 12, p. 1441.
  - (2021), Dassault Systèmes. BIOVIA Discovery Studio Visualizer; San Diego, CA, USA: 2021." Version v21 1.
  - Daura, X.  
**Peptide folding: when simulation meets experiment**  
(1998) *Angew. Chem. Int. Ed. Engl.*, 31.
  - Fung, T.S., Liu, D.X.  
**Post-translational modifications of coronavirus proteins: roles and function**  
(2018) *Future Virol.*, 13, pp. 405-430.  
(Preprint at)
  - Genheden, S., Ryde, U.  
**The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities**  
(2015) *Expert Opin. Drug Discov.*, 10, pp. 449-461.  
(Preprint at)
  - Hermann, J., Schurgers, L., Jankowski, V.  
**Identification and characterization of post-translational modifications: Clinical implications**  
(2022) *Mol. Asp. Med*, 86.
  - Ibrahim, Z.  
**In-Silico identification of potential protein arginine deiminase IV (PAD4) inhibitors**  
(2016) *Malays. J. Anal. Sci.*, 20, pp. 1269-1277.
  - Jain, C.K., Gupta, M., Prasad, Y., Wadhwa, G., Sharma, S.K.  
**Homology modeling and protein engineering of alkane monooxygenase in Burkholderia thailandensis MSMB121: in silico insights**  
(2014) *J. Mol. Model*, 20.
  - Knuckley, B., Bhatia, M., Thompson, P.R.  
**Protein Arginine Deiminase 4: evidence for a reverse protonation mechanism**  
(2007) *Biochemistry*, 46, pp. 6578-6587.
  - Knuckley, B., Causey, C.P., Pellechia, P.J., Cook, P.F., Thompson, P.R.  
**Haloacetamide-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation**  
(2010) *ChemBioChem*, 11, pp. 161-165.
  - Koushik, S.  
**PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis**  
(2017) *Expert Opin. Ther. Targets*, 21, pp. 433-447.
  - Kresten, L.L.  
**Improved side-chain torsion potential for the Amberff99SB protein force field. Protein**  
(2010), 78, pp. 1950-1958.

- Lewis, H.D.  
**Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation**  
(2015) *Nat. Chem. Biol.*, 11, pp. 189-191.
- Messaoudi, A., Belguith, H., Hamida, J.B.  
(2013) *Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1  $\beta$ -lactamase*,
- Mondal, S., Thompson, P.R.  
**Protein Arginine Deiminases (PADs): biochemistry and chemical biology of protein citrullination**  
(2019) *Acc. Chem. Res*, 52, pp. 818-832.
- Mondal, S., Thompson, P.R.  
**Chemical biology of protein citrullination by the protein A arginine deiminases**  
(2021) *Curr. Opin. Chem. Biol.*, 63, pp. 19-27.
- Olsen, I., Singhrao, S.K., Potempa, J.  
**Citrullination as a plausible link to periodontitis, rheumatoid arthritis, atherosclerosis and Alzheimer's disease.**  
(2018) *J. Oral. Microbiol*, 10, p. 1487742.
- Pettersen, E.F.  
**UCSF Chimera—a visualization system for exploratory research and analysis.**  
(2004) *J. Comput. Chem.*, 25, pp. 1605-1612.
- Purohit, R.  
**Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight**  
(2014) *J. Biomol. Struct. Dyn.*, 32, pp. 1033-1046.
- Ramazi, S., Zahiri, J.  
**Post-translational modifications in proteins: resources, tools and prediction methods**  
(2021) *Database*, 2021, p. baab012.
- Ranganathan, S.  
**Structural and functional mapping of ars gene cluster in *Deinococcus indicus* DR1**  
(2022) *Comput. Struct. Biotechnol. J.*,
- Sousa da Silva, A.W., Vranken, W.F.  
**ACPYPE - AnteChamber PYthon Parser interface**  
(2012) *BMC Res. Notes*, 5, p. 367.
- Steinborner, S.T., Bowie, J.H.  
**The negative ion mass spectra of [M-H]<sup>-</sup> ions derived from caeridin and dynastin peptides. internal backbone cleavages directed through Asp and Asn residues**  
(1997) *Rapid Commun. Mass Spectrom.*, 11, pp. 253-258.
- Teo, C.Y.  
**Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening**  
(2012) *BMC Bioinformatics*, 13, p. S4.
- Trott, O., Olson, A.J.  
**AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading**  
(2009) *J. Comput. Chem.*,
- Valdés-Tresanco, M.S., Valdés-Tresanco, M.E., Valiente, P.A., Moreno, E.  
**gmx\_MMPBSA: a new tool to perform end-state free energy calculations with**

**GROMACS**

(2021) *J. Chem. Theory Comput.*, 17, pp. 6281-6291.

- Virág, D.  
**Current trends in the analysis of post-translational modifications**  
(2020) *Chromatographia*, 83.  
(Preprint at)
- Yang, C.  
**Peptidylarginine deiminases 4 as a promising target in drug discovery**  
(2021) *Eur. J. Med. Chem.*, 226.  
(Preprint at)
- Yusuf, I.O.  
**Protein citrullination marks myelin protein aggregation and disease progression in mouse ALS models**  
(2022) *Acta Neuropathol. Commun.*, 10, p. 135.
- Zhang, H.  
**Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5**  
(2021) *Nat. Commun.*, 12.
- Zhang, W.  
**Upregulation of BMSCs osteogenesis by positively-charged tertiary amines on polymeric implants via charge/iNOS signaling pathway**  
(2015) *Sci. Rep.*, 5.
- Zhao, L., Zhao, J., Zhong, K., Tong, A., Jia, D.  
**Targeted protein degradation: mechanisms, strategies and application**  
(2022) *Signal Transduct. Target. Ther.*, 7.  
(Preprint at)
- Zhu, W.  
**Enhancing the thermal stability of glutathione bifunctional synthase by B-factor strategy and un/folding free energy calculation**  
(2022) *Catalysts*, 12.

**Correspondence Address**

Ibrahim Z.; Department of Pharmaceutical Chemistry, Indera Mahkota, Pahang, Malaysia; email: zalikha@iiium.edu.my

**Publisher:** Elsevier Ltd

**ISSN:** 14769271

**Language of Original Document:** English

**Abbreviated Source Title:** *Comput. Biol. Chem.*

2-s2.0-85174839825

**Document Type:** Article

**Publication Stage:** Final

**Source:** Scopus

---

**ELSEVIER**

Copyright © 2023 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

 RELX Group™